PCSK9-IN-10 - CAS 368434-98-4

PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 μM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.

Serine/threonin kinase, LDLR, Others

Cell Cycle/Checkpoint, Others, Metabolism

368332

0.9906

C18H23N5O4

373.41

COCCNc1nc2n(C)c(=O)n(C)c(=O)c2n1Cc1cccc(OC)c1

-20°C

Ice Packs

Small Compound